發(fā)布時間：2018-08-28 12:55

【摘要】：目的探討乳腺癌新輔助化療期間雌激素(ER)、孕激素受體(PR)狀態(tài)的改變及臨床指導意義。方法回顧分析208例2011年1月-2015年9月期間于重慶醫(yī)科大學附屬第一醫(yī)院行乳腺癌術前新輔助化療的局部晚期乳癌患者的資料,包括新輔助化療前核心穿刺標本的ER、PR表達情況以及術后病檢標本的ER、PR表達情況,隨訪內(nèi)分泌治療的使用情況,利用統(tǒng)計學方法進行生存分析,評估預后。結果新輔助化療前后ER、PR的表達約有21.2%的不一致性,κ值為0.519,提示新輔助化療前后激素受體(HR)狀態(tài)一致性差,其中新輔助化療后HR的丟失更為顯著(14.3%),新輔助化療前HR(ER/PR)陽性的患者使用內(nèi)分泌治療在無病生存率以及總生存率上顯著優(yōu)于新輔助化療前HR陰性,新輔助化療后HR陽性的患者(P0.05),而新輔助化療前HR陰性,新輔助化療后HR陽性的患者與新輔助化療前后HR均為陰性,未使用內(nèi)分泌治療的患者在無病生存率以及總生存率上無顯著性差異(P0.05)。結論對于新輔助化療前后HR表達改變的患者,新輔助化療前HR陽性的患者使用內(nèi)分泌治療療效明顯優(yōu)于新輔助化療前HR陰性、新輔助化療后HR陽性的患者,這類患者使用內(nèi)分泌治療療效不佳,提示新輔助化療增加了化療后乳腺癌組織免疫組化中HR的假陽性率,對于新輔助化療前核心穿刺病理標本HR陰性,新輔助化療后殘余癌組織中HR陽性的患者可能不必使用輔助內(nèi)分泌治療。
[Abstract]:Objective to investigate the changes of estrogen (ER), progesterone receptor (PR) status during neoadjuvant chemotherapy in breast cancer and its clinical significance. Methods the data of 208 patients with locally advanced breast cancer who received preoperative neoadjuvant chemotherapy in the first affiliated Hospital of Chongqing Medical University from January 2011 to September 2015 were retrospectively analyzed. The expression of ER,PR in core puncture specimens before neoadjuvant chemotherapy and ER,PR expression in post-operative biopsy specimens were included. The use of endocrine therapy was followed up and survival analysis was carried out using statistical methods to evaluate the prognosis. Results the expression of ER,PR before and after neoadjuvant chemotherapy was about 21.2%, and the 魏 value was 0.519, which suggested that the state of hormone receptor (HR) was poor before and after neoadjuvant chemotherapy. The loss of HR after neoadjuvant chemotherapy was more significant (14.3%). The disease-free survival rate and overall survival rate of patients with positive HR (ER/PR) before neoadjuvant chemotherapy were significantly higher than those without HR before neoadjuvant chemotherapy. The patients with HR positive after neoadjuvant chemotherapy (P0.05) were negative for HR before neoadjuvant chemotherapy, HR positive after neoadjuvant chemotherapy and HR before and after neoadjuvant chemotherapy. There was no significant difference in disease-free survival rate and overall survival rate between patients without endocrine therapy (P0.05). Conclusion for patients with HR expression before and after neoadjuvant chemotherapy, patients with positive HR before neoadjuvant chemotherapy are significantly better than those with HR negative before and after neoadjuvant chemotherapy, and patients with HR positive after neoadjuvant chemotherapy are better than those with positive HR before and after neoadjuvant chemotherapy. The effect of endocrine therapy on these patients was not good, suggesting that neoadjuvant chemotherapy increased the false positive rate of HR in breast cancer tissues after chemotherapy, and negative HR for core biopsy specimens before neoadjuvant chemotherapy. Patients with HR positive in residual neoadjuvant chemotherapy may not need adjuvant endocrine therapy.
【學位授予單位】：重慶醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R737.9

【參考文獻】

相關期刊論文 前10條

1 賈巍;張紅真;王文娟;趙光遠;姜玉榮;李海平;;新輔助化療前后乳腺癌免疫組化表達變化的研究分析[J];浙江醫(yī)學;2016年14期

2 周曉芳;王增;李楚倩;;乳腺癌新輔助化療前后ER、PR、Ki-67和Her-2變化[J];中國婦幼健康研究;2016年03期

3 ;中國抗癌協(xié)會乳腺癌診治指南與規(guī)范(2015版)[J];中國癌癥雜志;2015年09期

4 包剛;;乳腺癌新輔助化療療效與雌、孕激素受體表達的變化[J];貴陽醫(yī)學院學報;2015年07期

5 林思園;張利華;李想娣;;新輔助化療后乳腺癌雌激素受體、孕激素受體和人類表皮生長因子受體2狀態(tài)的改變[J];實用醫(yī)學雜志;2015年12期

6 蔣奕;葉新青;黃俊淇;韋常宏;葉洪濤;;乳腺癌新輔助化療前后分子標記物變化及其與療效的關系[J];廣西醫(yī)科大學學報;2015年02期

7 孫巖;袁淵;江偉;曹國春;陳穎波;朱敬華;;乳腺癌新輔助化療前后ER、PR和HER-2表達的變化[J];江蘇醫(yī)藥;2014年23期

8 徐揚;白云潮;胡超;;新輔助化療對局部晚期乳腺癌組織中雌激素受體孕激素受體和人表皮生長因子受體2表達的影響[J];中國腫瘤臨床與康復;2014年10期

9 朱思吉;陳小松;吳佳毅;黃歐;何建蓉;朱麗;陳偉國;李亞芬;費曉春;金曉龍;沈坤煒;;新輔助化療對乳腺癌激素受體、Her-2及Ki67的影響及其臨床意義[J];外科理論與實踐;2014年05期

10 張紅蕾;章來長;劉沖;;乳腺癌新輔助化療對雌激素受體孕激素受體人表皮生長因子受體和Ki67抗原標記指數(shù)表達的影響及意義[J];中國腫瘤臨床與康復;2013年02期

相關碩士學位論文 前2條

1 楊帆;乳腺癌新輔助化療前后生物學因子表達變化的臨床研究[D];甘肅中醫(yī)藥大學;2016年

2 張碩;乳腺癌新輔助化療前后ER、PR、Her-2、Ki67的變化分析[D];浙江大學;2012年

，

本文編號：2209458